Exegenesis Bio

Exegenesis Bio is a clinical stage global gene therapy company with operations in Philadelphia, Boston and China. The companys innovative gene therapy pipeline is based on proprietary capsids, promoters and unique protein engineering designs. Two programs have advanced to the clinical stage: (1) Type I Spinal Muscular Atrophy (SMA) AAV gene therapy in China (2) neurovascular AMD (wet AMD) rAAV gene therapy in USA The company has built state-of-the-art cGMP manufacturing facilities that include 500L and 2,000L disposable bioreactors for viral vectors and 30L disposable fermenters for plasmids. Exegenesis Bio has raised over $150 M since inception in 2019 and...

Gene therapy,biotechnology,cell therapy,aav,spinal muscular atrophy,eye diseases,hemophilia,cns diseases,liver-directed diseases,manufacturing,and lentivirus

Exegenesis bio operates in the Biotechnology research industry.

Exegenesis bio's revenue is 11m - 100m

Exegenesis bio has 11 - 50 employees.